Description
UBE3A polyclonal Antibody | BS8036 | Gentaur UK, US & Europe Distribution
Host: Rabbit
Reactivity: Human,Mouse,Rat
Application: WB IHC
Application Range: WB: 1:500~1:2000 IHC: 1:50~1:200
Background: E6-associating protein (E6-AP), also designated ubiquitin protein ligase E3A (UBE3A), is a component of the ubiquitin-mediated proteolytic pathway that selectively targets proteins for degradation by the 26S proteasome. Ubiquitin (Ub) is directly conjugated to protein substrates by the transfer of Ub from an E2 ubiquitin conjugating enzyme to the target protein. This conjugation is facilitated by the enzymatic activity of E3 ubiquitin ligase family members such as E6-AP. Several substrates of E6-AP have been identified and include the tumor suppressor protein p53 and the mammalian homolog of Rad23, HHR23A. Previous studies have indicated that E6-AP associates with the human papillomavirus E6 oncogene, which forms a complex with p53 and thereby potentiates E6-AP mediated ubiquitination of p53. Genetic mutations that impair E6-AP activity result in the accumulation of p53 in the cytoplasm, and in many instances, these mutations are associated with the development of the rare neurodevelopmental disorder Angelman syndrome (AS), which is characterized by severe motor dysfunction and mental retardation.
Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
Specificity: UBE3A polyclonal Antibody detects endogenous levels of UBE3A protein.
Molecular Weight: ~ 101 kDa
Note: For research use only, not for use in diagnostic procedure.
Alternative Names: Ubiquitin-protein ligase E3A; E6AP ubiquitin-protein ligase; Human papillomavirus E6-associated protein; Oncogenic protein-associated protein E6-AP; Renal carcinoma antigen NY-REN-54; UBE3A; E6AP; EPVE6AP; HPVE6A
Immunogen: Recombinant full length Human UBE3A.
Conjugate: Unconjugated
Modification: Unmodification
Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .
Pathway: